Albarasin, Neslie N.
HRN: 21-64-48 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/23/2022
CEFUROXIME 500MG (TAB)
07/23/2022
07/30/2022
ORAL
500mg
Q12
UTI
Waiting Final Action
Indication: Empiric Type of Infection: Urinary TractSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes